After a research note raised potential safety concerns with Amgen's lead obesity candidate, the company defended its drug and ...

Mr. Lavoie's extensive background includes a proven track record in structuring ... SOURCE Alithya Canada inc. Merck , known as MSD outside of the United States and Canada, announced today that Joseph ...

The company is paying China-based biotech LaNova Medicines $588 million for the kind of dual-pronged antibody drug that ...

Merck's undervalued stock presents growth opportunities with Keytruda and promising pipeline drugs, making it a Buy despite ...

(Reuters) -Merck has signed a licensing agreement worth up to $3.3 billion with Shanghai-based LaNova Medicines to develop, make and sell an experimental cancer drug, the two companies said on ...

"Having walked in the shoes of parent, nurse, and physician, Dr. McMahon brings a very unique and vital perspective to our Board," said Melmark President and CEO Rita M. Gardner, M.P.H., LABA, BCBA, ...

“I decided instead of buying an apartment on The World, I would build a ship myself. I have a background in architecture and ...

Alphabet's Q3 results show strong revenue and operating income growth, but declining free cash flow. Read why I think GOOG ...

Over the last 2 decades, significant progress has been made in our understanding of the genomics, tumor immune microenvironment, and immunogenicity of malignant melanoma. Historically, the prognosis ...

Procter & Gamble Health Ltd., incorporated in the year 1967, is a Mid Cap company (having a market cap of Rs 9,246.19 Crore) operating in Pharmaceuticals sector. Procter & Gamble Health Ltd. key ...